EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants

Fabrice F Darche iD, Lisa C Fabricius, Matthias Helmschrott, Ann-Kathrin Rahm iD, Philipp Ehlermann, Tom Bruckner, Wiebke Sommer, Gregor Warnecke, Norbert Frey, Rasmus Rivinius iD

Journal of Clinical Medicine · 28.06.2023 · 12 (13) · 4334

DOI: 10.3390/jcm12134334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.06.2023. Verfasst von Fabrice F Darche und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, 69120 Heidelberg, Germany. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Coeur - Daniel Wagner, Fondation de Luxembourg, Olympia-Morata-Program of the Faculty of Medicine, University of Heidelberg, German Heart Foundation/German Foundation of Heart Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients after heart transplantation (HTX) often require oral anticoagulants (OACs) due to atrial arrhythmias or thromboembolic events but little is known about the post-transplant use of direct oral anticoagulants (DOACs). We investigated the frequency, indications, and complications of DOACs and vitamin K antagonists (VKAs) after HTX.

Methods

We screened all adult patients for the use of post-transplant OACs who underwent HTX at Heidelberg Heart Center between 2000 and 2021. Patients were stratified by type of OAC (DOAC or VKA) and by DOAC agents (apixaban, dabigatran, edoxaban, or rivaroxaban). Indications for OACs comprised atrial fibrillation, atrial flutter, pulmonary embolism, upper and lower extremity deep vein thrombosis, as well as intracardiac thrombus.

Results

A total of 115 of 459 HTX recipients (25.1%) required OACs, including 60 patients with DOACs (52.2%) and 55 patients with VKAs (47.8%). Concerning DOACs, 28 patients were treated with rivaroxaban (46.7%), 27 patients with apixaban (45.0%), and 5 patients with edoxaban (8.3%). We found no significant differences between both groups concerning demographics, immunosuppressive drugs, concomitant medications, indications for OACs, ischemic stroke, thromboembolic events, or OAC-related death. Patients with DOACs after HTX had a significantly lower one-year rate of overall bleeding complications (p = 0.002) and a significantly lower one-year rate of gastrointestinal hemorrhage (p = 0.011) compared to patients with VKAs after HTX in the Kaplan–Meier estimator.

Conclusions

DOACs were comparable to VKAs concerning the risk of ischemic stroke, thromboembolic events, or OAC-related death but were associated with significantly fewer bleeding complications in HTX recipients.

Schlagwörter

Stichwörter der Autor:innen

atrial fibrillationbleedingdirect oral anticoagulantheart transplantationoral anticoagulantstrokevitamin K antagonist

Autor:innen und Institutionen

  • Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120 Heidelberg, Germany.
  • Institute for Medical Biometry, University of Heidelberg, 69120 Heidelberg, Germany.
  • Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.

ORCID-Profile: Fabrice F Darche, Ann-Kathrin Rahm, Rasmus Rivinius

Förderung

  • Fondation Coeur - Daniel Wagner, Fondation de Luxembourg
  • Olympia-Morata-Program of the Faculty of Medicine, University of Heidelberg
  • German Heart Foundation/German Foundation of Heart Research
  • Fondation Coeur—Daniel Wagner, Fondation de Luxembourg

Zitieren

APA

Darche, F. F., Fabricius, L. C., Helmschrott, M., Rahm, A. K., Ehlermann, P., Bruckner, T., Sommer, W., Warnecke, G., Frey, N., & Rivinius, R. (2023). Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants. Journal of Clinical Medicine, 12(13), 4334. https://doi.org/10.3390/jcm12134334

Vancouver

Darche FF, Fabricius LC, Helmschrott M, Rahm AK, Ehlermann P, Bruckner T, et al. Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants. Journal of Clinical Medicine. 2023;12(13):4334. doi:10.3390/jcm12134334

BibTeX
@article{Darche2023,
  author = {Darche, Fabrice F and Fabricius, Lisa C and Helmschrott, Matthias and Rahm, Ann-Kathrin and Ehlermann, Philipp and Bruckner, Tom and Sommer, Wiebke and Warnecke, Gregor and Frey, Norbert and Rivinius, Rasmus},
  title = {Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {13},
  pages = {4334},
  doi = {10.3390/jcm12134334}
}
Kostenlos starten →